Cargando…
Mucopolysaccharidosis III: Molecular basis and treatment
Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, I...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228206/ https://www.ncbi.nlm.nih.gov/pubmed/34743503 http://dx.doi.org/10.5114/pedm.2021.109270 |
_version_ | 1785050918284165120 |
---|---|
author | Spahiu, Lidvana Behluli, Emir Peterlin, Borut Nefic, Hilada Hadziselimovic, Rifat Liehr, Thomas Temaj, Gazmend |
author_facet | Spahiu, Lidvana Behluli, Emir Peterlin, Borut Nefic, Hilada Hadziselimovic, Rifat Liehr, Thomas Temaj, Gazmend |
author_sort | Spahiu, Lidvana |
collection | PubMed |
description | Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options. |
format | Online Article Text |
id | pubmed-10228206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-102282062023-06-05 Mucopolysaccharidosis III: Molecular basis and treatment Spahiu, Lidvana Behluli, Emir Peterlin, Borut Nefic, Hilada Hadziselimovic, Rifat Liehr, Thomas Temaj, Gazmend Pediatr Endocrinol Diabetes Metab Review paper | Praca poglądowa Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options. Termedia Publishing House 2021-09-30 2021-09 /pmc/articles/PMC10228206/ /pubmed/34743503 http://dx.doi.org/10.5114/pedm.2021.109270 Text en Copyright © Polish Society of Pediatric Endocrinology and Diabetes https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), allowing third parties to download and share its works but not commercially purposes or to create derivative works. |
spellingShingle | Review paper | Praca poglądowa Spahiu, Lidvana Behluli, Emir Peterlin, Borut Nefic, Hilada Hadziselimovic, Rifat Liehr, Thomas Temaj, Gazmend Mucopolysaccharidosis III: Molecular basis and treatment |
title | Mucopolysaccharidosis III: Molecular basis and treatment |
title_full | Mucopolysaccharidosis III: Molecular basis and treatment |
title_fullStr | Mucopolysaccharidosis III: Molecular basis and treatment |
title_full_unstemmed | Mucopolysaccharidosis III: Molecular basis and treatment |
title_short | Mucopolysaccharidosis III: Molecular basis and treatment |
title_sort | mucopolysaccharidosis iii: molecular basis and treatment |
topic | Review paper | Praca poglądowa |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228206/ https://www.ncbi.nlm.nih.gov/pubmed/34743503 http://dx.doi.org/10.5114/pedm.2021.109270 |
work_keys_str_mv | AT spahiulidvana mucopolysaccharidosisiiimolecularbasisandtreatment AT behluliemir mucopolysaccharidosisiiimolecularbasisandtreatment AT peterlinborut mucopolysaccharidosisiiimolecularbasisandtreatment AT nefichilada mucopolysaccharidosisiiimolecularbasisandtreatment AT hadziselimovicrifat mucopolysaccharidosisiiimolecularbasisandtreatment AT liehrthomas mucopolysaccharidosisiiimolecularbasisandtreatment AT temajgazmend mucopolysaccharidosisiiimolecularbasisandtreatment |